Table 1. Patients’ characteristics: untreatment and treatment related.
| Clinicopathologic characteristics | IL-2-treated patients (N=60) n. cases (%) | Untreated patients (N=33) n. cases (%) |
|---|---|---|
| Age | ||
| Range | 41–77 years | 54–81 years |
| Median | 62.5 years | 70.0 years |
| Gender | ||
| Male | 51 (85%) | 26 (78.8%) |
| Female | 9 (15%) | 7 (21.2%) |
| Histologic subtypes | ||
| Epithelioid | 46 (76.7%) | 25 (75.8%) |
| Biphasic | 9 (15.0%) | 3 (9.0%) |
| Sarcomatoid | 5 (8.3%) | 5 (15.2%) |
| IMIG stage | ||
| IB | 1 (1.7%) | |
| II | 15 (25.0%) | 16 (48.5%) |
| III | 44 (73.3%) | 17 (51.5%) |
| ECOG performance status | ||
| 0 | 8 (13.3%) | 6 (18.2%) |
| 1 | 34 (56.7%) | 20 (60.6%) |
| 2 | 18 (30.0%) | 7 (21.2%) |
| Recurrence (valid n 60) | ||
| Yes | 41 | |
| Local | 33 | |
| Local+sistemic | 7 | |
| Sistemic | 1 | |
| No | 19 | |
| Overall survival (valid n 60) | ||
| Range | 2–60 months | |
| Median | 13 months | |
| Time to progression (valid n 45) | ||
| Range | 1–57 months | |
| Median | 12 months | |
Abbreviations: IMIG=International Mesothelioma interest Group; ECOG=Eastern Cooperative Oncology Group.